Roth Capital Partners acted as Co-Manager
for Immunic, Inc. (Nasdaq:IMUX)
in its $45 Million Follow-On

For more information please contact:
 
Investment Banking
James Antonopoulos
Managing Director &
Head of Healthcare
Investment Banking
(646) 358-1906
jantonopoulos@roth.com
 
Aparna Beeram
Vice President
(646) 358-1912
abeeram@roth.com
 
Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703
agurewitz@roth.com
 
Nazan Akdeniz
Senior Vice President
(949) 720-5740
nakdeniz@roth.com
 
Lou Ellis
Senior Vice President
(949) 720-5739
lellis@roth.com

Transaction Information
Immunic, Inc.(Nasdaq: IMUX), announced the closing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $10.00 per share.

The Company received total proceeds from the offering, before deducting the underwriting discounts and other offering expenses, of $45.0 million.

The Company intends to use the net proceeds of the offering to fund the ongoing clinical development of its three lead product candidates, IMU-838, IMU-935 and IMU-856, and for other general corporate purposes.

Roth Capital Partners acted as co-manager for the offering.

About Immunic, Inc.
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For more information, please visit www.Imux.com. (Source: Company Press Release | 07.19.21)

About Roth Capital Partners
Roth Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, Roth provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, Roth is privately-held and employee owned, and maintains offices throughout the U.S. For more information on Roth, please visit www.roth.com.


About Roth  |  Investment Banking  |  Capital Markets  |  Institutional Sales & Trading
Research  |  Corporate Services  |  Corporate Access & Conferences  |  Press Room


Date of Announcement: 08.20.21
 
The material, information and  facts discussed in this announcement other than the information regarding Roth Capital Partners, LLC ("Roth") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of Roth. Copyright 2021.